Recombinant Peptides as Biomarkers for Tumor Response to Molecular Targeted Therapy

Abstract

The use of recombinant peptides to assess the pharmacodynamic response of cancer holds promise in minimizing the duration of ineffective treatment regimens in patients, potentially providing a more rapid and less invasive assessment of cancer response to systemic therapy.